2026-07-21T11:48:50Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/56682025-03-24T16:05:44Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16978

00925njm 22002777a 4500 dc Aldámiz-Echevarria, Teresa author Berenguer, Juan author Miralles, Pilar author Jimenez-Sousa, Maria Angeles author Carrero, Ana author Pineda-Tenor, Daniel author Díez, Cristina author Tejerina, Francisco author Pérez-Latorre, Leire author Bellón, José María author Resino, Salvador author 2016-02-05 BACKGROUND: Higher serum levels of adhesion molecules (sICAM-1 and sVCAM-1) are associated with advanced liver fibrosis in patients coinfected with human immunodeficiency virus and hepatitis C virus. We assessed the relationship between serum levels of adhesion molecules and liver-related events (LRE) or death, in coinfected patients. METHODS: We studied clinical characteristics and outcomes of 182 coinfected patients with a baseline liver biopsy (58 with advanced fibrosis) and simultaneous plasma samples who were followed for median of 9 years. We used receiver-operating characteristic (ROC) curves to calculate optimized cutoff values (OCV) of sICAM-1 and sVCAM-1, defined as the values with the highest combination of sensitivity and specificity for LRE. We used multivariate regression analysis to test the association between OCVs of sICAM-1 and sVCAM-1 and outcomes. The variables for adjustment were age, HIV transmission category, liver fibrosis, baseline CD4+ T-cell counts, antiretroviral therapy, and sustained virologic response (SVR). RESULTS: During the study period 51 patients had SVR, 19 had LRE, and 16 died. The OCVs for LRE were 5.68 Log pg/mL for sICAM-1 and 6.25 Log pg/mL for sVCAM-1, respectively. The adjusted subhazard ratio (aSHR) (95% confidence interval [CI]) of death or LRE, whichever occurred first, for sICAM-1 and sVCAM-1 > OCV were 3.98 ([1.14; 13.89], P = 0.030) and 2.81 ([1.10; 7.19], respectively (P = 0.030). CONCLUSIONS: Serum levels of sICAM-1 and sVCAM-1 can serve as markers of outcome in HIV/HCV-coinfected patients. Therapies targeting necroinflammatory damage and fibrogenesis may have a role in the management chronic hepatitis C. PLoS One. 2016; 11(2): e0148537 10.1371/journal.pone.0148537 1932-6203 PloS one 26849641 http://hdl.handle.net/20.500.12105/5668 Adult Biomarkers CD4-Positive T-Lymphocytes Coinfection Female Follow-Up Studies HIV Infections Hepatitis C Humans Intercellular Adhesion Molecule-1 Kaplan-Meier Estimate Liver Cirrhosis Male Retrospective Studies Vascular Cell Adhesion Molecule-1 Soluble Adhesion Molecules in Patients Coinfected with HIV and HCV: A Predictor of Outcome